Did you know that peri-menopause and menopause affects over 13 million women in the UK?
18th October 2023
13th October 2023
The first group of volunteers has been dosed and further groups will participate in the study over the coming months.
2nd October 2023
The study will be conducted by Hammersmith Medicines Research (HMR; London) and enrol up to 24 women to investigate the safety, tolerability and pharmacokinetics of testosterone delivered from Medherant TEPI Patch whe
11th September 2023
11 September 2023 (Coventry, UK). Medherant announces that Dr Karolina Afors BSC MBBS MRCOG has joined the company in the newly-created role of Medical Director to lead the clinical development of the
5th April 2023
3 April 2023. Medherant (Coventry, UK) announces that it has raised £2.9m of new funding from investors in a financing round led by Mercia Asset Management.
4th May 2020
Cambridge & Coventry, UK – 5 May 2020 – Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (Medherant) are pleased to announce that they have signed an agreement to develop and commercialize mult
23rd September 2019
Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch
25th June 2019
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a u
14th June 2019
Medherant enjoyed a great evening at the Midlands BVCA Management Team Awards last night.
21st May 2019
Coventry, UK, 21st May 2019 / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS dise